Alignment Healthcare, Inc. Common Stock
ALHC
$20.26
-10.12%
Alignment Healthcare, Inc. is a technology-enabled Medicare Advantage platform company that provides consumer-centric healthcare plans and services to seniors. It operates as a niche player in the managed care industry, distinguishing itself through a direct-to-consumer sales model and a proprietary clinical platform designed to improve health outcomes. The current investor narrative is heavily influenced by regulatory updates from the Centers for Medicare & Medicaid Services (CMS), with a recent larger-than-expected payment increase for 2027 boosting sector-wide sentiment and revenue visibility for Medicare Advantage insurers like Alignment.…
ALHC
Alignment Healthcare, Inc. Common Stock
$20.26
ALHC 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alignment Healthcare, Inc. Common Stock's 12-month outlook, with a consensus price target around $26.34 and implied upside of +30.0% versus the current price.
Average Target
$26.34
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$16 - $26
Analyst target range
Analyst coverage for Alignment Healthcare is limited, with only 6 analysts providing estimates, indicating it is a smaller, less-followed name which can lead to higher volatility. The available data shows consensus estimates for future performance, with an average EPS forecast of $1.67 and average revenue forecast of $13.65 billion, but a consensus price target and explicit buy/hold/sell distribution are not provided in the dataset, preventing a calculation of implied upside. The institutional ratings data shows a generally bullish tilt among the firms that do cover the stock, with recent actions including 'Overweight' from JP Morgan and Piper Sandler, and 'Buy' from TD Cowen. However, the presence of 'Neutral' ratings from UBS and 'Equal Weight' from Barclays indicates some caution. The most recent rating change was an upgrade by JP Morgan from 'Neutral' to 'Overweight' in November 2025, which could be a positive signal. The lack of a defined target price range in the provided data points to higher uncertainty and a wider dispersion of potential outcomes, which is common for companies in a high-growth, pre-profitability phase.
Bulls vs Bears: ALHC Investment Factors
The bull case for ALHC is anchored in its blistering 44% revenue growth and deeply discounted valuation below 1x sales, suggesting the market has over-penalized the stock. The bear case focuses on the inconsistent profitability, high leverage, and extreme volatility that make it a risky proposition. Currently, the bearish evidence holds more weight due to the concrete financial risks—the volatile path to profit and high debt—which are immediate concerns, while the bullish arguments are more forward-looking. The single most important tension in the investment debate is whether the company's explosive top-line growth can soon translate into sustainable and expanding profitability, justifying a re-rating from its current distressed valuation multiple.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue grew 44.43% year-over-year to $1.01 billion, demonstrating a clear multi-quarter acceleration. This top-line expansion, driven by the Health Care Premium segment, validates the company's direct-to-consumer model and market share gains in the Medicare Advantage space.
- Attractive Valuation on Sales: The stock trades at a trailing Price-to-Sales (PS) ratio of 0.99 and EV/Sales of 1.00, a significant discount from its IPO-era multiples above 13x. For a company growing revenue over 40%, this sub-1x sales multiple suggests the market is pricing in excessive pessimism, leaving room for multiple expansion.
- The company generated $123.7 million in trailing twelve-month free cash flow, a critical milestone that mitigates near-term solvency concerns. This shift towards self-funding operations reduces reliance on external capital and supports continued investment in growth.
- Favorable Regulatory Catalyst: The recent larger-than-expected 2027 Medicare Advantage payment increase from CMS provides a sector-wide tailwind. This boosts revenue visibility for Alignment and improves the fundamental backdrop for its core business, as noted in recent news driving sector sentiment.
Bearish
- Inconsistent Path to Profitability: The company swings between profit and loss, with Q4 2025 showing a net loss of $11.0 million after a $3.7 million profit in Q3. Gross margin also compressed from 12.65% in Q3 to 10.47% in Q4, highlighting volatile and pressured earnings as it scales.
- High Financial Leverage: The debt-to-equity ratio is elevated at 1.89, indicating significant financial leverage. This increases financial risk and interest expense burden, which totaled $3.95 million in Q4, especially in a higher-rate environment.
- Extreme Stock Volatility: The stock has a maximum drawdown of -41.15% over the observed period and has underperformed the S&P 500 by 14.22 points over the past three months. This high volatility, coupled with a short ratio of 4.91, reflects significant market skepticism and risk.
- Negative Return Metrics: Key profitability metrics are deeply negative, with a trailing Return on Equity (ROE) of -0.004 and a negative net margin. The forward P/E of 27.85, while positive, is high and hinges entirely on achieving analyst EPS estimates of $1.67, which is not guaranteed.
ALHC Technical Analysis
The stock is in a volatile, range-bound consolidation phase within a broader recovery context. Over the past year, the price has gained 20.81%, but the current price of $20.26 sits at approximately 68% of its 52-week range ($11.625 to $23.87), indicating it is positioned in the upper-mid range, having retreated from recent highs. This positioning suggests the stock is not at an extreme, but the journey from the 52-week low has been significant, with the price now consolidating after a sharp rally. Recent momentum shows a stark divergence from the longer-term trend. The stock posted a strong 13.50% gain over the past month, significantly outperforming the S&P 500's 9.98% return, as indicated by a positive 3.52 relative strength. However, this contrasts sharply with a 10.08% decline over the past three months, where it underperformed the market by 14.22 points. This divergence suggests the recent monthly surge may be a recovery bounce within a short-term downtrend that began in late January. Key technical support is anchored at the 52-week low of $11.625, while immediate resistance is at the 52-week high of $23.87. A breakout above $23.87 would signal a resumption of the primary uptrend, while a breakdown below recent lows around $16.62 (from late March) could test deeper support. The stock exhibits high volatility, with a maximum drawdown of -41.15% over the observed period, underscoring the need for careful risk management despite the recent positive price action.
Beta
1.20
1.20x market volatility
Max Drawdown
-41.1%
Largest decline past year
52-Week Range
$12-$24
Price range past year
Annual Return
+20.8%
Cumulative gain past year
| Period | ALHC Return | S&P 500 |
|---|---|---|
| 1m | +13.5% | +9.9% |
| 3m | -10.1% | +3.6% |
| 6m | +20.2% | +6.7% |
| 1y | +20.8% | +27.1% |
| ytd | +0.2% | +5.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALHC Fundamental Analysis
Alignment Healthcare's revenue trajectory is robust and accelerating. For Q4 2025, revenue reached $1.013 billion, representing a substantial 44.43% year-over-year growth. This growth is part of a clear multi-quarter acceleration, as revenue increased sequentially from $926.9M in Q1 to over $1.0B in Q2, Q3, and Q4 of 2025. The primary driver is the Health Care Premium segment, which contributed $425.82 million in the latest period, indicating strong member growth and premium intake. The company's path to profitability remains inconsistent, showing significant quarter-to-quarter volatility. While it reported a net loss of $11.0 million in Q4 2025, this followed a profitable Q3 with net income of $3.7 million. The gross margin for Q4 was 10.47%, a compression from the 12.65% gross margin seen in Q3 2025. This fluctuating profitability, against a backdrop of high growth, is typical for a company investing heavily in member acquisition and platform scaling within the capital-intensive Medicare Advantage sector. The balance sheet shows moderate leverage but strong liquidity from recent operations. The debt-to-equity ratio is elevated at 1.89, indicating significant financial leverage. However, liquidity is solid with a current ratio of 1.74. Crucially, the company generated $123.7 million in trailing twelve-month free cash flow, a positive signal that it is beginning to fund operations internally. The return on equity is negative at -0.004, reflecting the net loss position, but the improving cash flow trend mitigates near-term solvency concerns.
Quarterly Revenue
$1.0B
2025-12
Revenue YoY Growth
+0.44%
YoY Comparison
Gross Margin
+0.10%
Latest Quarter
Free Cash Flow
$123672000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALHC Overvalued?
Given the company's negative trailing net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. Alignment trades at a trailing PS ratio of 0.99 and an Enterprise Value-to-Sales (EV/Sales) of 1.00. The absence of a meaningful forward PS in the data limits a growth expectation analysis based on this multiple, but the sub-1.0x sales multiple is a key focal point. Compared to industry averages, a PS ratio below 1.0x is generally considered low for a healthcare services company, especially one with over 40% revenue growth. This suggests the market is applying a significant discount, likely due to the company's lack of consistent profitability and the capital-intensive, competitive nature of the Medicare Advantage market. The discount reflects skepticism about the sustainability of growth and the path to normalized margins. Historically, the stock's own valuation provides critical context. The current PS ratio of 0.99 is near the bottom of its observable historical range, which has extended above 13x sales at its IPO in 2021. This dramatic compression from historical highs indicates the market has severely de-rated the stock, moving from pricing hyper-growth expectations to a more conservative, cash-flow-focused model. Trading at these lows suggests the stock is pricing in significant fundamental risks, leaving room for multiple expansion if execution improves.
PE
-5401.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -99x~233x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
81.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced. The company's inconsistent profitability, evidenced by a Q4 net loss of $11.0 million following a Q3 profit, creates earnings volatility that undermines valuation stability. Gross margin compression from 12.65% to 10.47% quarter-over-quarter signals potential pricing pressure or rising medical costs. The elevated debt-to-equity ratio of 1.89 increases financial risk, making the company more vulnerable to rising interest rates and economic downturns. While positive TTM free cash flow of $123.7 million provides a buffer, the business model remains capital-intensive as it scales member acquisition.
Market & Competitive Risks center on valuation and sector dynamics. Trading at a PS ratio of 0.99, the stock appears cheap, but this discount reflects deep-seated skepticism about its ability to achieve normalized margins in the highly competitive Medicare Advantage market dominated by giants like UnitedHealth and Humana. The stock's high volatility (max drawdown -41.15%) and negative 3-month relative strength of -14.22 indicate it is prone to sharp sell-offs during market stress. While the recent CMS payment news is a positive sector catalyst, any future regulatory tightening or rate cuts could reverse this sentiment, compressing sector multiples.
Worst-Case Scenario involves a perfect storm of execution missteps and macro headwinds. This would entail a significant deceleration in revenue growth below 20%, coupled with further gross margin erosion below 10%, leading to larger-than-expected losses. This could trigger a liquidity crisis given the high leverage, force dilutive equity raises, and result in a loss of investor confidence. In this adverse scenario, the stock could realistically retest its 52-week low of $11.625, representing a downside of approximately -43% from the current price of $20.26. A break below this level could see further declines given the lack of consistent earnings support.